Sarepta Therapeutics Q2 Adj EPS $(0.85) Beats $(1.89) Estimate, Sales $261.24M Miss $264.45M Estimate
Portfolio Pulse from totan@benzinga.com
Sarepta Therapeutics reported Q2 adjusted EPS of $(0.85), beating the estimate of $(1.89) by 55.03%. However, the company's sales of $261.24M missed the estimate of $264.45M by 1.21%. The EPS is a 27.97% increase from last year, while the sales represent an 11.89% increase from the same period last year.
August 04, 2023 | 12:25 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Sarepta Therapeutics reported better than expected Q2 EPS but missed on sales. The EPS beat could drive positive sentiment, while the sales miss may cause concern.
Sarepta Therapeutics reported a significant beat on EPS, which is likely to be viewed positively by investors. However, the company missed on sales, which could cause some concern. The net impact on the stock is uncertain in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100